Health Catalyst, Inc. (NASDAQ:HCAT) Given Average Recommendation of “Moderate Buy” by Brokerages

Health Catalyst, Inc. (NASDAQ:HCAT) has been given an average recommendation of “Moderate Buy” by the eleven ratings firms that are covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $12.09.

HCAT has been the topic of a number of research reports. Wells Fargo & Company dropped their price objective on Health Catalyst from $14.00 to $13.00 and set an “overweight” rating on the stock in a research note on Friday, May 10th. Piper Sandler cut their price objective on Health Catalyst from $15.00 to $14.00 and set an “overweight” rating on the stock in a report on Thursday, June 6th. KeyCorp restated a “sector weight” rating on shares of Health Catalyst in a report on Wednesday, April 10th. Canaccord Genuity Group restated a “buy” rating and set a $11.00 price objective on shares of Health Catalyst in a report on Tuesday, May 21st. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a research report on Wednesday, April 10th.

Health Catalyst Stock Performance

HCAT opened at $6.10 on Friday. Health Catalyst has a one year low of $5.45 and a one year high of $14.37. The stock’s fifty day moving average is $6.47 and its 200-day moving average is $7.89. The company has a market capitalization of $360.08 million, a PE ratio of -3.30 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. Health Catalyst had a negative return on equity of 11.86% and a negative net margin of 35.56%. The company had revenue of $74.72 million for the quarter, compared to the consensus estimate of $74.81 million. On average, equities research analysts forecast that Health Catalyst will post -0.4 EPS for the current fiscal year.

Hedge Funds Weigh In On Health Catalyst

Large investors have recently made changes to their positions in the business. Valmark Advisers Inc. bought a new stake in shares of Health Catalyst in the 4th quarter valued at approximately $1,204,000. Primecap Management Co. CA grew its stake in shares of Health Catalyst by 26.7% in the 4th quarter. Primecap Management Co. CA now owns 1,419,577 shares of the company’s stock valued at $13,145,000 after buying an additional 299,139 shares in the last quarter. Nepsis Inc. grew its stake in shares of Health Catalyst by 20.5% in the 4th quarter. Nepsis Inc. now owns 1,091,932 shares of the company’s stock valued at $10,111,000 after buying an additional 186,128 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Health Catalyst by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 6,441,707 shares of the company’s stock valued at $65,190,000 after buying an additional 78,823 shares in the last quarter. Finally, MQS Management LLC bought a new stake in shares of Health Catalyst in the 3rd quarter valued at approximately $116,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.